Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic

References

• McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med.334, 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst.92, 699–708 (2000).
   PubMed Web of Science ®Google Scholar
• Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol.18, 3084–3092 (2000).
   PubMed Web of Science ®Google Scholar
• Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol.18, 106–115 (2000).
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol.21, 3194–3200 (2003).
   PubMed Web of Science ®Google Scholar
• du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst.95, 1309–1329 (2003).
   Google Scholar
• Mano MS, Awada A, Minisini A et al. Remaining controversies in the upfront management of advanced ovarian cancer. Int. J. Gynecol. Cancer14, 707–720 (2004).
   Google Scholar
• Gadducci A, Sartori E, Maggino T et al. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol. Oncol.68, 150–155 (1998).
   Google Scholar
• Thigpen JT. Current controversies in ovarian cancer: maintenance chemotherapy as standard care. In: American Society of Clinical Oncology, 2004 Educational Book, Perry MC (Ed.). 40th Annual Meeting, June 5–8 2004, New Orleans, LA, Alexandria (VA), 281–284 (2004).
   Google Scholar
• Bell DA. Origins and molecular pathology of ovarian cancer. Mod. Pathol.18(Suppl.), S19–S32 (2005).
   Google Scholar
• Loor F, Tiberghien F, Wenandy T, Didier A, Traber R. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter. J. Med. Chem.45, 4598–4612 (2002).
   PubMed Web of Science ®Google Scholar
• Loor F. Valspodar: current status and perspectives. Expert Opin. Investig. Drugs8, 807–835 (1999).
   PubMedGoogle Scholar
• Tai HL. Technology evaluation: valspodar, novartis AG. Curr. Opin. Mol. Ther.2, 459–467 (2000).
   Google Scholar
• Sonneveld P, Marie JP, Huisman C et al. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A Phase I study. Leukemia10, 1741–1750 (1996).
   PubMed Web of Science ®Google Scholar
• Tidefelt U, Liliemark J, Gruber A et al. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J. Clin. Oncol.18, 1837–1844 (2000).
   PubMed Web of Science ®Google Scholar
• Baekelandt M, Lehne G, Trope CG et al. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J. Clin. Oncol.19, 2983–2993 (2001).
   PubMed Web of Science ®Google Scholar
• Fracasso PM, Brady MF, Moore DH et al. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol.19, 2975–2982 (2001).
   PubMed Web of Science ®Google Scholar
• Duraj J, Sedlak J, Bies J, Chovancova J, Chorvath B. PSC 833 modulation of multidrug resistance to paclitaxel in cultured human ovarian carcinoma cells leads to apoptosis. Anticancer Res.22, 3425–3428 (2002).
   Google Scholar
• Kavallaris M, Leary JA, Barrett JA, Friedlander ML. MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett.102, 7–16 (1996).
   PubMed Web of Science ®Google Scholar
• Safa AR. Multidrug resistance. In: Principles of antineoplastic drug development and pharmacology. Schilsky RL, Milano GA, Ratain MJ (Eds). Marcel Dekker, NY, USA, 457–486 (1996).
   Google Scholar
• Rosenfeld ME, Feng M, Michael SI, Siegal GP, Alvarez RD, Curiel DT. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin. Cancer Res.1, 1571–1580 (1995).
   PubMedGoogle Scholar
• Plautz G, Nabel EG, Nabel GJ. Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biol.3, 709–715 (1991).
   PubMedGoogle Scholar
• Link CJ, Seregina T, Traynor A, Burt RK. Cellular suicide therapy of malignant disease. Oncologist5, 68–74 (2000).
   Google Scholar
• Al-Hendy A, Magliocco AM, Al-Tweigeri T et al. Ovarian cancer gene therapy: repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. Am. J. Obstet. Gynecol.182, 553–559 (2000).
   PubMedGoogle Scholar
• Alvarez RD, Gomez-Navarro J, Wang M et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol. Ther.2, 524–30 (2000).
   PubMed Web of Science ®Google Scholar
• McNeish IA, Tenev T, Bell S, Marani M, Vassaux G, Lemoine N. Herpes simplex virus thymidine kinase/ganciclovir-induced cell death is enhanced by co-expression of caspase-3 in ovarian carcinoma cells. Cancer Gene Ther.8, 308–319 (2001).
   Google Scholar
• Ziller C, Lincet H, Muller CD, Staedel C, Behr JP, Poulain L. The cyclin-dependent kinase inhibitor p21(cip1/waf1) enhances the cytotoxicity of ganciclovir in HSV-tk transfected ovarian carcinoma cells. Cancer Lett.212, 43–52 (2004).
   PubMed Web of Science ®Google Scholar
• Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs60(Suppl. 1), 15–23 (2000).
   PubMed Web of Science ®Google Scholar
• Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol.20, 4292–4302 (2002).
   PubMed Web of Science ®Google Scholar
• Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin. Oncol.30(Suppl.), 3–14 (2003).
   Web of Science ®Google Scholar
• Mass RD. The HER receptor family: a rich target for therapeutic development. Int. J. Radiat. Oncol. Biol. Phys.58, 932–940 (2004).
   PubMedGoogle Scholar
• Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Semin. Oncol.30(Suppl.), 34–46 (2003).
   PubMed Web of Science ®Google Scholar
• Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr. Cancer Drug Targets5, 171–193 (2005).
   PubMed Web of Science ®Google Scholar
• Toi M, Horiguchi K, Bando H, Saji S, Chow LW. Trastuzumab: updates and future issues. Cancer Chemother. Pharmacol.56(Suppl.), 94–99 (2005).
   PubMedGoogle Scholar
• De Laurentiis M, Cancello G, Zinno L et al. Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann. Oncol.16(Suppl.), 7–13 (2005).
   Google Scholar
• Santoro A, Cavina R, Latteri F et al. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann. Oncol.15, 33–37 (2004).
   PubMedGoogle Scholar
• Brown ER, Shepherd FA. Erlotinib in the treatment of non-small cell lung cancer. Expert Rev. Anticancer Ther.5, 767–775 (2005).
   PubMed Web of Science ®Google Scholar
• Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol.23, 3227–3234 (2005).
   PubMed Web of Science ®Google Scholar
• Riely GJ, Pao W, Pham D et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res.12, 839–844 (2006).
   PubMed Web of Science ®Google Scholar
• Bartlett JM, Langdon SP, Simpson BJ et al. The prognostic valued of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer73, 301–306 (1996).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244, 707–712 (1989).
   PubMed Web of Science ®Google Scholar
• Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res.50, 4087–4091 (1990).
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Boyer CM, Jacobs I et al. Cell growth regulation in epithelial ovarian cancer. Cancer71(Suppl), 1597–601 (1993).
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Ranelletti FO, Lauriola L et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol. Oncol.85, 305–310 (2002).
   PubMed Web of Science ®Google Scholar
• Lee CH, Huntsman DG, Cheang MC et al. Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int. J. Gynecol. Pathol.24, 147–152 (2005).
   Google Scholar
• Rahaman J, Nagarsheth N, Nezhat F, Cohen C, Kalir T. The prognostic significance of epidermal growth factor receptor (EGFR) expression in ovarian cancer (OC) metastasis. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 5067).
   Google Scholar
• Blank SV, Chang R, Muggia F. Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer. Oncology19, 553–559 (2005).
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Sill MW, Chen X et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin. Cancer Res.11, 5539–5548 (2005).
   PubMed Web of Science ®Google Scholar
• Blank SV, Curtin JP, Goldman NA et al. Tolerability of carboplatin, paclitaxel and erlotinib as first-line treatment of ovarian cancer. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 5052).
   Google Scholar
• Fujimura M, Hidaka T, Saito S. Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells. Clin. Cancer Res.8, 2448–2454 (2002).
   PubMedGoogle Scholar
• Aghajanian C, Sabbatini P, Derosa F et al. A Phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 5047).
   Google Scholar
• Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol.21, 283–290 (2003).
   PubMed Web of Science ®Google Scholar
• Camilleri-Broët S, Guastalla JP, Couturier J et al. HER2 overexpression and amplification in advanced ovarian cancer (OC): preliminary results from a large GINECO study. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 5059).
   Google Scholar
• Fujimura M, Katsumata N, Tsuda H et al. HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn. J. Cancer Res.93, 1250–1257 (2002).
   PubMedGoogle Scholar
• Iwamoto H, Fukasawa H, Honda T, Hirata S, Hoshi K. HER-2/neu expression in ovarian clear cell carcinomas. Int. J. Gynecol. Cancer13, 28–31 (2003).
   Google Scholar
• Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol.23, 2534–2543 (2005).
   PubMed Web of Science ®Google Scholar
• Gordon MS, Matei D, Aghajanian C et al. Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 5051).
   Google Scholar
• Campos S, Hamid O, Seiden MV et al. Multicenter, randomized Phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J. Clin. Oncol.23, 5597–5604 (2005).
   PubMed Web of Science ®Google Scholar
• Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin. Oncol.29(Suppl.), 80–85 (2001).
   Google Scholar
• Capdeville R, Silberman S, Dimitrijevic S. Imatinib: the first 3 years. Eur. J. Cancer38(Suppl.), S77–S82 (2002).
   Google Scholar
• Schmandt RE, Broaddus R, Lu KH et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer98, 758–764 (2003).
   PubMed Web of Science ®Google Scholar
• Matei D, Emerson RE, Lai YCet al. Autocrine activation of PDGFRα promotes the progression of ovarian cancer. Oncogene25, 2060–2069 (2006)
   PubMed Web of Science ®Google Scholar
• Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRα, and PDGFRβ in ovarian cancers. Hum. Pathol.36, 242–249 (2005).
   PubMed Web of Science ®Google Scholar
• Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivation. Clin. Cancer Res.10, 681–690 (2004).
   PubMed Web of Science ®Google Scholar
• Dushkin H, Schilder RJ. Imatinib mesylate and its potential implications for gynecologic cancers. Curr. Treat. Options Oncol.6, 115–120 (2005).
   Google Scholar
• Pant DK, Ghosh A. A systems biology approach for the study of cumulative oncogenes with applications to the MAPK signal transduction pathway. Biophys. Chem.119, 49–60 (2006).
   Google Scholar
• Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell93, 53–62 (2001).
   PubMed Web of Science ®Google Scholar
• Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol.30(Suppl.), 105–116 (2003).
   PubMed Web of Science ®Google Scholar
• Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J. Biol. Chem.720, 14843–14846 (1995).
   Google Scholar
• Grammer TC, Blenis J. Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene14, 1635–1642 (1997).
   PubMed Web of Science ®Google Scholar
• Camps M, Nichols A, Gillieron C et al. Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science280, 1262–1265 (1998).
   PubMed Web of Science ®Google Scholar
• Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Eur. J. Biochem.270, 3291–3299 (2003).
   PubMedGoogle Scholar
• Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci.20, 117–122 (1995).
   PubMed Web of Science ®Google Scholar
• Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest.99, 1478–1483 (1997).
   PubMed Web of Science ®Google Scholar
• Kim S, Hahn J, Min Y, Yoo N, Ko Y, Lee W. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood93, 3893–3899 (1999).
   PubMed Web of Science ®Google Scholar
• Barry OP, Mullan B, Sheehan D et al. Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent. J. Biol. Chem.276, 15537–15546 (2001).
   PubMedGoogle Scholar
• Ahmed N, Pansino F, Baker M, Rice G, Quinn M. Association between avB6 integrin expression, elevated p42/44 MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J. Cell. Biochem.84, 675–686 (2002).
   PubMed Web of Science ®Google Scholar
• Weber A, Hengge UR, Urbanik D et al. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab. Invest.83, 1771–1776 (2003).
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417, 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen Y, Xing M, Mambo E et al. BRAF mutations in papillary thyroid carcinoma. J. Natl Cancer Inst.16, 625–627 (2003).
   Google Scholar
• Singer G, Oldt R 3rd, Cohen Y et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl Cancer Inst.95, 484–486 (2003).
   PubMed Web of Science ®Google Scholar
• Steinmetz R, Wagoner HA, Zeng P et al. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol. Endocrinol.18, 2570–2582 (2004).
   PubMed Web of Science ®Google Scholar
• Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science297, 1018–1023 (2002).
   PubMed Web of Science ®Google Scholar
• Lin Y, Chuang S, Yang J. ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. J. Biol. Chem.278, 21534–21541 (2003).
   PubMed Web of Science ®Google Scholar
• Basso AD, Mirza A, Liu G, Long BJ, Bishop WR, Kirschmeier P. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem.280, 31101–31108 (2005).
   PubMed Web of Science ®Google Scholar
• Caponigro F, Basile M, de Rosa V, Normanno N. New drugs in cancer therapy, National Tumor Institute, Naples, 17–18 June 2004. Anticancer Drugs16, 211–221 (2005).
   Google Scholar
• Macdonald JS, McCoy S, Whitehead RP et al. A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest. New Drugs23, 485–487 (2005).
   PubMed Web of Science ®Google Scholar
• Ahmad T, Eisen T. Kinase inhibition with BAY 43–9006 in renal cell carcinoma. Clin. Cancer Res.10, S6388–S6392 (2004).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J. Clin. Oncol.23, 965–972 (2005).
   PubMed Web of Science ®Google Scholar
• Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43–9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res.11, 5472–5480 (2005).
   PubMed Web of Science ®Google Scholar
• Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist.11, 753–764 (2006).
   PubMed Web of Science ®Google Scholar
• Eto M, Naito S. Molecular targeting therapy for renal cell carcinoma. Int. J. Clin. Oncol.11, 209–213 (2006).
   Google Scholar
• de Castro G Jr, Puglisi F, de Azambuja E, El Saghir NS, Awada A. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the ‘do ut des’ paradigm). Crit. Rev. Oncol. Hematol.59, 40–50 (2006).
   Google Scholar
• Singer G, Stohr R, Cope L et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol.29, 218–224 (2005).
   PubMed Web of Science ®Google Scholar
• Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih IeM. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res.65, 1994–2000 (2005).
   Google Scholar
• Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem. Biol.2, 503–508 (1995).
   PubMed Web of Science ®Google Scholar
• Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ.6, 303–313 (1999).
   PubMed Web of Science ®Google Scholar
• Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol.8, 739–758 (2001).
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Small GW, Shi YY. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J. Biol. Chem.277, 27864–27871 (2002).
   PubMed Web of Science ®Google Scholar
• Magnani M, Crinelli R, Bianchi M, Antonelli A. The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-κB (NF-κB). Curr. Drug Targets1, 387–399 (2000).
   PubMedGoogle Scholar
• Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κ B1 precursor protein and the activation of NF-κ B. Cell78, 773–785 (1994).
   PubMed Web of Science ®Google Scholar
• Vlahakis SR, Badley AD. Influence of proteasome inhibitors on apoptosis. Curr. Opin. Clin. Nutr. Metab. Care9, 42–47 (2006).
   Google Scholar
• Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res.59, 2615–2622 (1999).
   PubMed Web of Science ®Google Scholar
• Ling YH, Liebes L, Jiang JD et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res.9, 1145–1154 (2003).
   PubMed Web of Science ®Google Scholar
• San Miguel J, Blade J, Boccadoro M et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist11, 51–61 (2006).
   PubMed Web of Science ®Google Scholar
• Cusack JC. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat. Rev.29, 21–31 (2003).
   PubMed Web of Science ®Google Scholar
• Aghajanian C. Clinical update: novel targets in gynecologic malignancies. Semin. Oncol.31, 22–26 (2004).
   Google Scholar
• Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J. Clin. Oncol.23, 5943–5949 (2005).
   PubMed Web of Science ®Google Scholar
• Brader S, Eccles SA. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori90, 2–8 (2004).
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med.10, 789–799 (2004).
   PubMed Web of Science ®Google Scholar
• Dudkin L, Dilling MB, Cheshire PJ et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res.7, 1758–1764 (2001).
   PubMed Web of Science ®Google Scholar
• Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol.3, 371–377 (2003).
   PubMed Web of Science ®Google Scholar
• Dutcher JP. Mammalian target of rapamycin inhibition. Clin. Cancer Res.10, S6382–S6387 (2004).
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly-targeted therapies. Crit. Rev. Oncol. Hematol.58, 242–256 (2006).
   PubMed Web of Science ®Google Scholar
• Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem.273, 14424–14429 (1998).
   PubMed Web of Science ®Google Scholar
• De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene23, 3189–3199 (2004).
   PubMed Web of Science ®Google Scholar
• Peralba JM, DeGraffenried L, Friedrichs W et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res.9, 2887–2892 (2003).
   PubMed Web of Science ®Google Scholar
• Mita MM, Mita A, Rowinski EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer4, 126–137 (2003).
   PubMedGoogle Scholar
• Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol.16, 525–537 (2005).
   PubMed Web of Science ®Google Scholar
• Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin. Investig. Drugs14, 313–328 (2005).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22, 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer100, 657–666 (2004).
   PubMed Web of Science ®Google Scholar
• Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res.64, 252–261 (2004).
   PubMed Web of Science ®Google Scholar
• Boni JP, Leister C, Bender G et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin. Pharmacol. Ther.77, 76–89 (2005).
   Google Scholar
• Feldman E, Giles F, Roboz G et al. A Phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 6631).
   Google Scholar
• Chawla SP, Sankala KK, Chua V et al. A Phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 9068).
   Google Scholar
• Xing D, Orsulic S. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc. Natl Acad. Sci. USA102, 6936–6941 (2005).
   PubMed Web of Science ®Google Scholar
• Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol. Ther.92, 57–70 (2001).
   PubMed Web of Science ®Google Scholar
• Lotan R. New strategies and agents for targeting apoptotic pathways for cancer prevention and therapy. Presented at: Twelfth International Congress on Anti-Cancer Treatment. Paris, France 4–7 (2002).
   Google Scholar
• Antonsson B. Bax and other pro-apoptotic Bcl-2 family ‘killer-proteins’ and their victim in the mitochondrion. Cell Tissue Res.306, 347–361 (2001).
   PubMed Web of Science ®Google Scholar
• Lane DP. p53, guardian of the genome. Nature538, 15–16 (1992).
   Google Scholar
• Gadducci A, Cosio S, Muraca S, Genazzani AR. Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. Eur. J. Gynaecol. Oncol.23, 390–396 (2002).
   PubMed Web of Science ®Google Scholar
• Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int. J. Biochem. Cell Biol.32, 1123–1136 (2000).
   PubMed Web of Science ®Google Scholar
• Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem. Soc. Trans.29, 684–688 (2001).
   PubMed Web of Science ®Google Scholar
• Gao CF, Ren S, Zhang L et al. Caspase-dependent cytosolic release of cytochrome c and membrane translocation of Bax in p53-induced apoptosis. Exp. Cell Res.265, 145–151 (2001).
   PubMed Web of Science ®Google Scholar
• Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol.2, 3009 (2001).
   Google Scholar
• Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, Takahashi R. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. J. Biol. Chem.276, 27058–27063 (2001).
   PubMedGoogle Scholar
• Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MRT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell85, 803–815 (1996).
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science281, 1305–1308 (1998).
   PubMed Web of Science ®Google Scholar
• Seol DW, Li J, Seol MH, Park SY, Talanian RV, Billiar TR. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res.61, 1138–1143 (2001).
   Google Scholar
• Perego P, Giarola M, Righetti SC et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res.56, 556–562 (1996).
   PubMed Web of Science ®Google Scholar
• Fajac A, Da Silva J, Ahomadegbe JC et al. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int. J. Cancer68, 67–74 (1996).
   Google Scholar
• Song K, Li Z, Seth P, Cowan KH, Sinha BK. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Oncol. Res.9, 603–609 (1997).
   Google Scholar
• Righetti SC, Della Torre G, Pilotti S et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res.56, 689–693 (1996).
   PubMed Web of Science ®Google Scholar
• Buttitta F, Marchetti A, Gadducci A et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br. J. Cancer75, 230–235 (1997).
   PubMed Web of Science ®Google Scholar
• Calvert AH, Ghokul S, Al-Azraqi A et al. Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene. Semin. Oncol.26(Suppl.), 90–94 (1999).
   Google Scholar
• Reles A, Wen WH, Schmider A et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res.7, 2984–2989 (2001).
   PubMed Web of Science ®Google Scholar
• Kigawa J, Sato S, Shimada M et al. p53 gene status and chemosensitivity in ovarian cancer. Hum. Cell14, 165–171 (2001).
   PubMedGoogle Scholar
• Gadducci A, Di Cristofano C, Zavaglia M et al. p53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel-plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res.26, 687–694 (2006).
   PubMed Web of Science ®Google Scholar
• Wolf JK, Bodurka DC, Gano JB et al. A Phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol. Oncol.94, 442–448 (2004).
   PubMed Web of Science ®Google Scholar
• Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol.4, 415–422 (2003).
   PubMed Web of Science ®Google Scholar
• McNeish IA, Lopes R, Bell SJ et al. Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp. Cell. Res.302, 69–82 (2005).
   Google Scholar
• Ma X, Wang S, Zhou J et al. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol. Rep.14, 275–279 (2005).
   Google Scholar
• Shao R, Lee DF, Wen Y et al. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. Mol. Cancer Res.3, 219–226 (2005).
   PubMed Web of Science ®Google Scholar
• Abdollahi T. Potential for TRAIL as a therapeutic agent in ovarian cancer. Vitam. Horm.67, 347–364 (2004).
   Google Scholar
• Ashkenazi A. Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat. Rev. Cancer2, 420–430 (2002).
   PubMed Web of Science ®Google Scholar
• Abe K, Kurakin A, Mohseni-Maybodi M, Kay B, Khosravi-Far R. The complexity of TNF-related apoptosis-inducing ligand. Ann. NY Acad. Sci.926, 52–63 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang X, Li P, Bao J et al. Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J. Biol. Chem.280, 35458–35468 (2005).
   PubMedGoogle Scholar
• Arts HJ, de Jong S, Hollema H, ten Hoor K, van der Zee AG, de Vries EG. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol. Oncol.92, 794–800 (2004).
   Google Scholar
• Hazelton DA, Hamilton TC. Vascular endothelial growth factor in ovarian cancer. Curr. Oncol. Rep.1, 59–63 (1999).
   PubMedGoogle Scholar
• Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol.2, 278–289 (2001).
   PubMed Web of Science ®Google Scholar
• Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol. Pathol.55, 348–359 (2002).
   PubMedGoogle Scholar
• Marshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin. Oncol.32(Suppl.), S43–S47 (2005).
   PubMedGoogle Scholar
• Hurwitz H, Kabbinavar F. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology69(Suppl.), 17–24 (2005).
   Google Scholar
• de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology69(Suppl), 46–56 (2005).
   PubMed Web of Science ®Google Scholar
• Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol. Oncol.96, 902–905 (2005).
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill M, Monk BJ, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 5009).
   Google Scholar
• Hata K, Osaki M, Dhar DK et al. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line. Cancer Chemother. Pharmacol.53, 68–74 (2004).
   Google Scholar
• Kudoh K, Kikuchi Y, Kita T et al. The effect of single weekly paclitaxel in heavily pretreated ovarian cancer patients and its antiangiogenic effects. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 5115).
   Google Scholar
• Garcia AA, Oza AM, Hirte H et al. Interim report of a Phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 5000).
   Google Scholar
• Dupont J, Rothenberg MK, Spriggs DR et al. Safety and pharmacokinetics of intravenous VEGF Trap in a Phase I clinical trial of patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 3029).
   Google Scholar
• Schroder W, Witteveen E, Abadie S et al. A Phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 in combination with paclitaxel and carboplatin in patients (PTs) with stage IIC to IV epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 5042).
   Google Scholar
• Kikuchi Y, Kita T, Takano M, Kudoh K, Yamamoto K. Treatment options in the management of ovarian cancer. Expert. Opin. Pharmacother.6, 743–754 (2005).
   PubMed Web of Science ®Google Scholar
• Kelland LR. Emerging drugs for ovarian cancer. Expert Opin. Emerg. Drugs10, 413–424 (2005).
   PubMedGoogle Scholar
• Bhoola SM, Alvarez RD. Novel therapies for recurrent ovarian cancer management. Expert Rev. Anticancer Ther.4, 437–448 (2004).
   PubMedGoogle Scholar
• Sharma S, Odunsi K. Targeted therapy for epithelial ovarian cancer. Expert Opin. Ther. Targets9, 501–513 (2005).
   PubMed Web of Science ®Google Scholar
• Ozols RF. Future directions in the treatment of ovarian cancer. Semin. Oncol.29(Suppl.), 32–42 (2002).
   PubMed Web of Science ®Google Scholar
• Posadas EM, Davidson B, Kohn EC. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Curr. Opin. Oncol.16, 478–484 (2004).
   PubMed Web of Science ®Google Scholar
• Espina V, Geho D, Mehta AI, Petricoin EF 3rd, Liotta LA, Rosenblatt KP. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest.23, 36–46 (2005).
   PubMed Web of Science ®Google Scholar
• Workman P. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Cancer Chemother. Pharmacol.52(Suppl.), S45–S56 (2003).
   Google Scholar
• Cheng KW, Lahad JP, Mills GB. Analysis of molecular aberrations in ovarian cancer allows novel target identification. J. Obstet. Gynaecol. Can.26, 461–474 (2004).
   Google Scholar
• Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov.1, 683–695 (2002).
   PubMed Web of Science ®Google Scholar
• Kohn EC, Mills GB, Liotta L. Promising directions for the diagnosis and management of gynecological cancers. Int. J. Gynaecol. Obstet.83(Suppl.), 203–209 (2003).
   Google Scholar
• Sheehan KM, Calvert VS, Kay EW et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol. Cell. Proteomics4, 346–355 (2005).
   PubMed Web of Science ®Google Scholar